Related Experiment Video

Updated: Jul 19, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Thiazolidinedione anti-cancer activity: Is inhibition of microtubule assembly implicated?

Wade A Russu1

  • 1Department of Pharmaceutics and Medicinal Chemistry, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, 3601 Pacific Avenue, Stockton, CA 95211, USA. wrussu@pacific.edu

Medical Hypotheses
|September 26, 2006
PubMed

Insights

Thiazolidinediones (TZDs), used for diabetes, may fight cancer by inhibiting microtubule assembly. This research explores their anti-cancer potential and suggests methods to confirm their mechanism of action.

Area of Science:

  • Pharmacology
  • Cell Biology
  • Oncology

Background:

  • Thiazolidinediones (TZDs) are primarily used for type 2 diabetes.
  • Emerging evidence suggests TZDs possess anti-cancer properties.
  • The precise mechanism behind TZD's anti-cancer activity remains unclear.

Purpose of the Study:

  • To hypothesize and investigate the anti-cancer activity of TZDs.
  • To explore the potential of TZDs as inhibitors of microtubule assembly.
  • To identify potential therapeutic applications for TZDs in cancer treatment.

Main Methods:

  • Literature review of empirical data on TZD effects.
  • Comparative analysis of TZD cellular effects with known microtubule inhibitors.
  • Identification of molecular structure similarities between TZDs and microtubule inhibitors.

Main Results:

  • TZDs exhibit similarities to known microtubule assembly inhibitors.
  • Observed effects include G1 phase cell cycle arrest, anti-angiogenesis, and inhibition of cell motility.
  • Alternative hypothesis suggests TZDs may inhibit actin polymerization.

Conclusions:

  • TZDs show promise as anti-cancer agents through microtubule inhibition.
  • Further research using tubulin polymerization assays and calorimetry is recommended.
  • Understanding TZD's anti-cancer role could revitalize the drug class.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...